APIC Tag

The guideline “Additional guidance on the assessment on the risk assessment for presence of N-nitrosamines in APIs”, first prepared in February 2020 by the APIC Nitrosamines Task Force on behalf of the Active Pharmaceutical Ingredient Committee (APIC), has now been revised by a subgroup of the APIC Nitrosamines Task Force to reflect latest guidance and recommended practice and recently published on the APIC website. The document is now called “Nitrosamine Risk Management: Guidance for API Manufacturers” and has been extensively updated.

Among the new features introduced, a separate chapter is dedicated to the incorporation of nitrosamine risk management into the quality management system.

 

SOURCES:

https://apic.cefic.org/wp-content/uploads/2025/05/APIC-Nitrosamines-Risk-management_Guidance-for-API-Manufacturers_Final.pdf

In January 2025, the Task Force “Data Integrity” of the Quality Group of APIC (CEFIC), has published the version 2.0 of the document “Data Integrity Frequently Asked Questions (FAQ)“.

This document contains a collection of frequently asked questions that have been submitted by the industry to the Data Integrity taskforce. Since this is a living document, it is updated as new questions are posed to the group.

Updated questions are written in red: the new questions and answers can be found in the “Password management” and “Access management” sections.

  1. Password management

Q1: When I logged into a system, do I need to re-authenticate myself for every data entry?

A: No, it depends upon the criticality of the data/action. This criticality should be based upon process mapping and a risk assessment as explained in the guide. Criticality of the data and/or responsibility associated with the action should be taken into account when evaluating electronic signature requirements.

Q2: What are the requirements for e-signature components? (This question in version 1 of the FAQ was worded differently whereas it has now been revised as above)

A: This practice is described in 21CFR11, chapter 11.200 “e-signature and components”:

(i) When an individual executes a series of signings during a single, continuous period of controlled system access, the first signing shall be executed using all electronic signature components (= user ID and password or biometrics); subsequent signings shall be executed using at least one electronic signature component that is only executable by, and designed to be used only by, the individual.

(ii) When an individual executes one or more signings not performed during a single, continuous period of controlled system access, each signing shall be executed using all of the electronic signature components

  1. Access management

Q2: Can we extend the time of a user session before this is automatically locked for inactivity because of a HSE (health-safety-environment) concern?

A: The inactive time of a user session should be managed by the user locking their computer station when they move away for an extend period of time to prevent unauthorised actions been taken by other persons. The automatic lock is a security measure. A reasonable amount of time should be supported by a risk assessment. This type of HSE concern should be managed independently of the GXP system with an emergency stop button as an example. If this is approach is not feasible, the computerized system should be designed as such that a fast intervention is possible. It is best practice for a system like a DCS to be configured in such a way that the screen does not completely goes into operating system lock and actions can be taken by clicking on the valve or object and entering a password to confirm the action.

 

SOURCES:

https://apic.cefic.org/wp-content/uploads/2025/01/FAQ-DI-APIC-TF-Version-2-Jan-25-1.pdf

The Version 17 of the “How to do” document – Interpretation of ICH Q7 Guide and “Review form” for APIs was finalized last November and published on the Active Pharmaceutical Ingredients Committee (APIC) website in early 2025.

The document aims to facilitate the implementation of the ICH Q7 guideline and provides recommendations for its interpretation.

In this version, additions and updates have been made in the following chapters:

  • Chapter 2 Quality Management
    • the changes were made in the subsections 2.1 Principles (10, 2.12, 2.14) and 2.2 Responsibilities of the Quality Unit(s) (2.21).
  • Chapter 5 Process Equipment
    • additions and innovations have been made in subsections: 5.2 Equipment Maintenance and Cleaning, 5.3 Calibration, and 5.4 Computerized Systems
  • Chapter 13 Change Control
    • updates concern items 10, 13.11, 13.12, 13.13, 13.14, 13.15.
  • Chapter 21 ICH Q7 Q&A “how to do” attachment (Questions and Answers linked to the respective sections of ICH Q7)
    • some Questions & Answers in Chapter 5 “Process Equipment – Cleaning” have been more clearly interpreted and aligned with the newly published guidelines.

SOURCE:

https://apic.cefic.org/wp-content/uploads/2025/01/ICH-Q7-How-To-Do-version17_cleandocument_241122.pdf